Anti-Human Siglec-2/CD22 Reference Antibody (M971, RUO) (HB011076)

Name: Anti-Human Siglec-2/CD22 Reference Antibody (M971, RUO)
Brand: abinScience
SKU: HB011076
Price: 176 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号	HB011076
説明	Anti-Human CD22 (M971) (HB011076) is a research-grade recombinant antibody targeting CD22. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性	Human
アプリケーション	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
宿主種	Human
クローン性	Monoclonal
アイソタイプ	IgG1
クローンID	M971
テスト済みアプリケーション	FCM
ターゲット	B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, CD22, SIGLEC2, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
エンドトキシンレベル	< 10 EU/mg
純度	>95% as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	P20273
形態	Liquid
保存バッファー	0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名	NCI-m971, NCIm971, NCIm971, DHD38514
背景	B-cell receptor CD22 is a ~95 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa). 1. Meyer, SJ. et al. (2021) Journal of immunology (Baltimore, Md. : 1950) 207, 1018-1032. PMID: 34330755 2. Law, CL. et al. (1996) The Journal of experimental medicine 183, 547-60. PMID: 8627166 3. Ramya, TN. et al. (2010) Molecular & cellular proteomics : MCP 9, 1339-51. PMID: 20172905 4. Séïté, JF. et al. (2010) Blood 116, 1698-704. PMID: 20516366
注意事項	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)

イメージ

SDS-PAGE

SDS-PAGE for Research Grade Anti-Human CD22 (M971).
Flow CytoMetry

Flow-cytometry using APC anti-human CD22 antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CD22 monoclonal antibody (Catalog: HB011076, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.
Flow CytoMetry

Flow-cytometry using FITC anti-human CD22 antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human CD22 monoclonal antibody (Catalog: HB011076, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.